Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) FCF Margin (2016 - 2025)

Anaptysbio filings provide 10 years of FCF Margin readings, the most recent being 130.66% for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 39840.0% year-over-year to 130.66%, compared with a TTM value of 11.2% through Dec 2025, up 24456.0%, and an annual FY2025 reading of 8.36%, up 15702.0% over the prior year.
  • FCF Margin hit 130.66% in Q4 2025 for Anaptysbio, up from 54.74% in the prior quarter.
  • The five-year high for FCF Margin was 130.66% in Q4 2025, with the low at 2503.96% in Q4 2021.
  • Median FCF Margin over the past 5 years was 250.18% (2021), compared with a mean of 682.16%.
  • The sharpest move saw FCF Margin crashed -256640bps in 2021, then soared 229084bps in 2022.
  • Year by year, FCF Margin stood at 2503.96% in 2021, then soared by 91bps to 213.12% in 2022, then plummeted by -78bps to 378.43% in 2023, then grew by 29bps to 267.74% in 2024, then surged by 149bps to 130.66% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 130.66%, 54.74%, and 181.05% for Q4 2025, Q3 2025, and Q2 2025 respectively.